Julie Côté

Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, Su J, Jimenez-Zepeda VH, Song K, Louzada M, White D, Sebag M, Reiman A, Stakiw J, Kotb R, Bergstrom D, Aslam M, Kaedbey R, Venner CP, Gul E, Reece D

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Blood Cancer J, 13 (1), 2023.

Résumé | Liens:

Stakiw J, Kodad S, LeBlanc R, Sebag M, Hay AE, Kukreti V, Côté J, Camacho F, Fu M, Gul E, Reece D

A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Clin Lymphoma Myeloma Leuk, 23 (7), 2023.

Résumé | Liens:

Côté J, Kotb R, Bergstrom DJ, LeBlanc R, Mian HS, Othman I, Louzada ML

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium

Clin Lymphoma Myeloma Leuk, 23 (5), 2023.

Résumé | Liens:

LeBlanc R, Bergstrom DJ, Côté J, Kotb R, Louzada ML, Sutherland HJ

Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium

Clin Lymphoma Myeloma Leuk, 22 (1), 2022.

Résumé | Liens: